Old drug, new hope: enasidenib may ease anemia in blood cancer patients
NCT ID NCT05282459
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested the drug enasidenib in 17 people with low-risk myelodysplastic syndrome or a related leukemia who had anemia and did not have a specific gene mutation. The goal was to see if the drug could safely improve red blood cell counts and reduce the need for transfusions. Researchers also looked at how the drug works to boost red blood cell production.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Enasidenib (Idhifa, AG 221)
- What this could lead to
- If successful, enasidenib could offer a new way to improve anemia and reduce blood transfusions for people with certain blood cancers.
- What could go wrong
- This is a very early, small study (17 people) with no placebo group, so results may not be reliable or apply to everyone. Side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford Cancer Institute
Palo Alto, California, 94305, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor's DNA guide better cancer care for kids?
- A guided path back to work after blood cancer: a trial tests the impact
- Can a new tracer light up cancer growth?
- Can a different immune drug cut viral infections after stem cell transplants?
- Can simple seated exercises boost strength and Well-Being during leukemia treatment?
- Can a Child's own words improve cancer care?